Sequential combination of high dose methotrexate and l-asparaginase followed by allogeneic transplant: A first-line strategy for CD4+/CD56+ hematodermic neoplasm

Leukemia and Lymphoma

Volumn 53, Issue 8, 2012, Pages 1633-1637

  Gilis, Lila ^a   Lebras, Laure ^a   Bouafia Sauvy, Fadhela ^a   Espinouse, Daniel ^a   Felman, Pascale ^b   Berger, Francoise ^c   Salles, Gilles ^a   Coiffier, Bertrand ^a   Michallet, Anne Sophie ^a  

^a Service Hématologie Clinique   (France)

^b Service Hématologie Biologique   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CD4 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ALLOTRANSPLANTATION; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; FEMALE; HEMATODERMIC NEOPLASM; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LETTER; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD56; ASPARAGINASE; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; LEUKEMIA; MALE; METHOTREXATE; MIDDLE AGED; SKIN NEOPLASMS; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84864266956     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.656627     Document Type: Letter

References (20)

1. A dachi M, Maeda K, Takekawa M, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol 1994 47:278-282.
2. Chaperot L, Bendriss N, Manches O, et al. Identifi cation of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001;97:3210-3217.
3. Jaye DL, Geigerman CM, Herling M, et al. Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4- CD56- hematodermic neoplasms. Mod Pathol 2006;19:1555-1562.
4. Burg G, Kempf W, Cozzio A, et al. WHO/EORTC classifi cation of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol 2005;32:647-674.
5. Petrella T, Dalac S, Maynadie M, et al. CD4- CD56- cutaneous neoplasms: a distinct hematological entity? Groupe Francais d'Etude des Lymphomes Cutanes (GFELC). Am J Surg Pathol 1999;23:137-146.
6. F euillard J, Jacob MC, Valensi F, et al. Clinical and biologic features of CD4(- ) CD56(- ) malignancies. Blood 2002;99:1556-1563.
7. P etrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4- CD56- hematodermic neoplasms): a review. Am J Clin Pathol 2005;123:662-675.
8. H erling M, Jones D. CD4- /CD56- hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol 2007;127:687-700.
9. Kohrt H, Advani R. Extranodal natural killer /T cell lymphoma: current concepts in biology and treatment. Leuk Lymphoma 2009;50: 1773-1784.
10. R eimer P, Rudiger T, Kraemer D, et al. What is CD4- CD56- malignancy and how should it be treated? Bone Marrow Transplant 2003;32:637-646.
11. Y amada O, Ichikawa M, Okamoto T, et al. Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies. Br J Haematol 2001;113:153-160.
12. Adachi M, Maeda K, Takekawa M, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol 1994;47:278-282.
13. Nagatani T, Okazawa H, Kambara T, et al. Cutaneous monomorphous CD4- and CD56-positive large-cell lymphoma. Dermatology 2000;200:202-208.
14. P etrella T, Comeau MR, Maynadie M, et al. " A granular CD4- CD56- hematodermic neoplasm " (blastic NK-cell lymphoma) originates from a population of CD56- precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002;26:852-862.
15. B ayerl MG, Rakozy CK, Mohamed AN, et al. Blastic natural killer cell lymphoma/leukemia: a report of seven cases. Am J Clin Pathol 2002;117:41-50.
16. K arube K, Ohshima K, Tsuchiya T, et al. Non-B, non-T neoplasms with lymphoblast morphology: further clarifi cation and classifi cation. Am J Surg Pathol 2003;27:1366-1374.
17. B ekkenk MW, Jansen PM, Meijer CJ, et al. CD56- hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004;15: 1097-1108.
18. Reichard KK, Burks EJ, Foucar MK, et al. CD4(- ) CD56(- ) lineagenegative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol 2005;29:1274-1283.
19. N g AP, Lade S, Rutherford T, et al. Primary cutaneous CD4- / CD56- hematodermic neoplasm (blastic NK-cell lymphoma): a report of fi ve cases. Haematologica 2006;91:143-144.
20. Ji H, Wang L, Li D, et al. CD4/CD56 hematodermic neoplasm: a report of three cases. Int J Dermatol 2009;48:743-748.